Cannabidiol, a Non-Psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells through a Multitarget Effect | Zendy

Marta Solinas | Zendy; Paola Massi | Zendy; Valentina Cinquina | Zendy; Marta Valenti | Zendy; Daniele Bolognini | Zendy; Marzia Bruna Gariboldi | Zendy; Elena Monti | Zendy; Tiziana Rubino | Zendy; Daniela Parolaro | Zendy

Open Access

Cannabidiol, a Non-Psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells through a Multitarget Effect

Author(s) -

Marta Solinas,

Paola Massi,

Valentina Cinquina,

Marta Valenti,

Daniele Bolognini,

Marzia Bruna Gariboldi,

Elena Monti,

Tiziana Rubino,

Daniela Parolaro

Publication year - 2013

Publication title -

plos one

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.99

H-Index - 332

ISSN - 1932-6203

DOI - 10.1371/journal.pone.0076918

Subject(s) - cannabidiol , glioma , pharmacology , mapk/erk pathway , cannabinoid , protein kinase b , angiogenesis , chemistry , cell growth , signal transduction , cancer research , biology , medicine , cannabis , biochemistry , receptor , psychiatry

In the present study, we found that CBD inhibited U87-MG and T98G cell proliferation and invasiveness in vitro and caused a decrease in the expression of a set of proteins specifically involved in growth, invasion and angiogenesis. In addition, CBD treatment caused a dose-related down-regulation of ERK and Akt prosurvival signaling pathways in U87-MG and T98G cells and decreased hypoxia inducible factor HIF-1α expression in U87-MG cells. Taken together, these results provide new insights into the antitumor action of CBD, showing that this cannabinoid affects multiple tumoral features and molecular pathways. As CBD is a non-psychoactive phytocannabinoid that appears to be devoid of side effects, our results support its exploitation as an effective anti-cancer drug in the management of gliomas.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research